Compare WBX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WBX | MREO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | Spain | United Kingdom |
| Employees | 696 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 52.5M |
| IPO Year | N/A | 2017 |
| Metric | WBX | MREO |
|---|---|---|
| Price | $3.23 | $0.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $4.75 | $1.50 |
| AVG Volume (30 Days) | 19.0K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $18.10 | $5,184.20 |
| Revenue Next Year | $94.11 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.20 |
| 52 Week High | $7.83 | $2.94 |
| Indicator | WBX | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 61.85 | 30.21 |
| Support Level | $2.84 | $0.20 |
| Resistance Level | $3.26 | $0.36 |
| Average True Range (ATR) | 0.21 | 0.02 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 91.86 | 17.39 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).